The TP53 mutations showed significant association with breast cancer subtypes (P<0.001) and had higher proportion of patients with basal-like (23.6% vs. 7.3%) and HER2-enriched (18.9% vs. 8.2%) tumors, comparing with non-TP53 mutations. This evidence concerns the gene TP53 and breast carcinoma.